Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors

US9957264B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Matthew L. Childers · Medfield, US
• Peter H. Fuller · Ashland, US
• David Joseph Guerin · Natick, US
• Jason Katz · Leominster, US
• Qinglin Pu · Needham, US
• Mark E. Scott · Fairfield, US
• Christopher F. Thompson · Arlington, US
• Michelle Martinez · Salem, US
• Danielle Falcone · Brookline, US
• Luis Torres · Norwood, US
• Yongqi Deng · Newton, US
• Ravi Kurukulasuriya · Gurnee, US
• Hongbo Zeng · Westford, US
• Yunfeng Bai · Beijing, CN
• Norman Kong · West Caldwell, US
• Yumei Liu · Beijing, CN
• Zhixiang Zheng · Beijing, CN

Key dates

• Filing date: Mar 19, 2014
• Grant date: May 1, 2018
• Expiry date: Mar 19, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.